Celcuity: What's Happening With CELC Stock?
Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single trading session, with shares rocketing from approximately $14 to a peak of $46 before stabilizing around $37. This dramatic price movement was triggered by positive topline results from the PIK3CA wild-type cohort of the company's Phase 3 VIKTORIA-1 clinical trial for gedatolisib, a targeted therapy for HR+/HER2- breast cancer.
The clinical results demonstrated that gedatolisib, when combined with one or two other medicines, significantly reduced the risk of disease progression or death compared to the control group. This outcome validates the company's therapeutic approach and positions the drug for potential regulatory submission.
Big Commercial Opportunity
Gedatolisib represents a substantial commercial opportunity with peak sales potential exceeding $2 billion. The drug targets hormone receptor-positive, HER2-negative breast cancer, a significant patient population with limited treatment options after endocrine therapy resistance develops. The FDA has already granted gedatolisib Breakthrough Therapy Designation, which could expedite the regulatory review process.
The company plans to file for FDA approval in Q4 2025, with additional Phase 3 trials (VIKTORIA-2) evaluating the drug as a first-line treatment already underway. This multi-indication strategy could expand the addressable market significantly.
Financial Flexibility
As a pre-revenue biotech company, Celcuity operates with an expected cash burn profile, recording operational cash outflows of $127 million over the last twelve months. The company recently announced its intention to conduct public offerings totaling $225 million, comprising $150 million in convertible senior notes due 2031 and $75 million in common stock. The proceeds will help fund clinical trials and research & development activities. This substantial capital raise aims to bolster financial flexibility and support ongoing oncology research, providing significant runway to advance clinical programs toward commercialization.
But There Are Risks
While Celcuity has shown promising clinical results, several significant risks could impact its future trajectory and the successful development and commercialization of its lead drug, gedatolisib.
Investment Outlook
The positive Phase 3 results represent a significant validation of Celcuity's platform and therapeutic approach. With regulatory submission planned for Q4 2025 and Breakthrough Therapy Designation already secured, the company appears well-positioned for potential approval. However, investors should carefully weigh the substantial commercial opportunity against the inherent risks associated with biotech development and regulatory approval processes.
The current valuation reflects significant optimism about regulatory success, making the investment sensitive to any setbacks in the approval timeline or additional clinical requirements from regulators. In fact, CELC stock is down 10% in extended trading post the dramatic 3x surge on Monday, July 28.
See, regulatory risk is just a small part of the risk assessment framework we apply while constructing the 30-stock Trefis High Quality (HQ) Portfolio, which has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Group says its homelessness prevention program needs more money from P.E.I. government
The John Howard Society of P.E.I. has been running a provincial pilot project called the Prevention and Diversion Fund, which provided vulnerable Islanders money to pay for things like first months' rent to prevent them from becoming homeless. Government was funding that program, but the society says it needs more money for the program to work. CBC's Tony Davis has more.
Yahoo
21 minutes ago
- Yahoo
Nutrien Declares Quarterly Dividend of US$0.545 per Share
SASKATOON, Saskatchewan, August 06, 2025--(BUSINESS WIRE)--Nutrien Ltd. (TSX and NYSE: NTR) announced today that its Board of Directors has declared a quarterly dividend of US$0.545 per share payable on October 17, 2025, to shareholders of record on September 29, 2025. Registered shareholders who are residents of Canada as reflected in Nutrien's shareholders register, as well as beneficial holders (i.e., shareholders who hold their common shares through a broker or other intermediary) whose intermediary is a participant in CDS Clearing and Depositary Services Inc. or its nominee, CDS & Co., will receive their dividend in Canadian dollars, calculated based on the Bank of Canada daily average exchange rate on September 29, 2025. Registered shareholders resident outside of Canada as reflected in Nutrien's shareholders register, including the United States, as well as beneficial holders whose intermediary is a participant in The Depository Trust Company or its nominee, Cede & Co., will receive their dividend in US dollars. However, registered shareholders of Nutrien may elect to change the currency of their dividend payments to US dollars or Canadian dollars, as applicable. In addition, Nutrien offers registered shareholders direct deposit by electronic funds transfer for dividend payments. Registered shareholders may elect to change the currency of their dividend and enroll for direct deposit by contacting, Nutrien's registrar and transfer agent, Computershare Investor Services Inc., directly (1-800-564-6253 or service@ Beneficial shareholders should contact their broker or other intermediary to determine the ability and necessary steps involved in an election to change the currency of their dividend payment. For further details, please visit All dividends paid by Nutrien are, pursuant to subsection 89(14) of the Income Tax Act (Canada), designated as eligible dividends. About Nutrien Nutrien is a leading global provider of crop inputs and services. We operate a world-class network of production, distribution and ag retail facilities that positions us to efficiently serve the needs of growers. We focus on creating long-term value by prioritizing investments that strengthen the advantages of our business across the ag value chain and by maintaining access to the resources and the relationships with stakeholders needed to achieve our goals. View source version on Contacts Jeff HolzmanSenior Vice President, Investor Relations and FP&A(306) 933-8545Contact us at: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Firefly Aerospace to price US IPO as it sets sights on a positive liftoff
By Pritam Biswas and Arasu Kannagi Basil (Reuters) -Northrop Grumman-backed Firefly Aerospace, the buzzy space technology startup that put a lander on the moon, is set to price its U.S. IPO later on Wednesday. In a nascent but rapidly growing commercial space industry, Firefly's IPO has attracted investor attention because it successfully landed its uncrewed Blue Ghost spacecraft on the moon in its first attempt in March. Cedar Park, Texas-based Firefly Aerospace is set to sell 16.2 million shares of its stock, priced between $41 and $43 apiece. This range was raised earlier this week, signaling strong demand. U.S. President Donald Trump's focus on commercializing space technology and safeguarding the national interests in space has attracted venture capital firms and billionaires. Elon Musk's SpaceX — the most valuable private company in the world — has become a critical part of the U.S. satellite network, even prompting a need across the government to look for more contractors. The U.S. government is betting that diversifying its contractor base will foster innovation and cut the huge costs of sending rockets to space, as well as reduce over-reliance on a single provider for critical missions. NASA's procurement process now includes new entrants such as Firefly Aerospace and Sierra Space, alongside legacy companies, leveraging commercial partnerships for lunar landers, space station modules and cargo deliveries. While space-related IPOs have been scarce in recent years, the tide is starting to turn in 2025. Firefly's listing comes on the heels of the successful New York flotations of space and defense firms Karman, AIRO Group and Voyager. As of Tuesday's close, shares of Karman have more than doubled from their offer price, while Voyager has gained 10%. "Given Firefly and the success of Voyager, I think you are going to see several more space-related companies test the waters of a public offering," said Ross Carmel, partner at law firm Sichenzia Ross Ference Carmel. TO THE MOON Formed in 2017, Firefly designs and manufactures small- to medium-lift launch vehicles, lunar landers and orbital vehicles. It had a backlog of roughly $1.1 billion and over 30 planned launches under contract as of March 31. While Houston-based Intuitive Machines' Odysseus lander was the first private lander to reach the moon last year, it made a lopsided touchdown, landing mostly intact but dooming many of its onboard instruments. Firefly's was the second, but its Blue Ghost spacecraft landed safely, reaching the moon's surface a month and a half after launching atop a SpaceX rocket from NASA's Kennedy Space Center in Florida. Last month, Firefly secured a $176.7 million contract to deliver five NASA payloads to the Moon's South Pole in 2029. Firefly was valued at more than $2 billion in a 2024 funding round. The company's backers include aerospace-focused private investment firm AE Industrial Partners. U.S. defense contractor Northrop Grumman, which invested $50 million into Firefly to aid the production of their jointly developed rocket, is one of three suppliers of solid rocket motors (SRMs) to the United States. Firefly is expected to begin trading on the Nasdaq under the ticker symbol "FLY" on Thursday.
